MSP-1014 / Mindset Pharma - LARVOL DELTA

Novel and promising treatments for anxiety disorders (WFSBP 2026) - "Results / Several compounds are in development, including drugs targeting the serotonin system (toludesvenlafaxine, gepirone, FKW00GA), the trace amine-associated receptor 1 (TAAR1), , the GABA binding site (ENX-102, darigabat, and buagafuran), the nicotinic receptor (soclenitant and VQW-765), the endocannabinoid system (cannabidiol and SYT-510), pherins (fasedienol) and psychedelics (MM120, PSX-001, MSP-1014). The translation of these compounds into clinically approved treatments for anxiety disorders may take several years, potentially delaying the emergence of significant therapeutic breakthroughs."

CNS Disorders • Mood Disorders • Psychiatry

The preclinical safety, behavioural and pharmacokinetics properties of MSP-1014, a novel prodrug of psilocin. (Neuroscience 2022) - "These data indicate that MSP-1014 is a rapidly metabolized prodrug of psilocin and is likely to exert similar effects to psilocybin in humans. The attenuation of reduced LMA and BT compared to psilocybin in mice suggests that tolerability of MSP-1014 may be superior to psilocybin."

PK/PD data • Preclinical • CNS Disorders • Depression • Psychiatry

Mindset Pharma Selects Treatment-Resistant Depression and End of Life Cancer Angst as Indications for MSP-1014, its Novel Psilocybin-Inspired Clinical Candidate (GlobeNewswire) - "Mindset Pharma Inc...today announced that it has selected Treatment-Resistant Depression ('TRD') and End of Life Angst as initial target indications for its lead clinical candidate, MSP-1014....'In a head-to-head comparison with psilocybin, MSP-1014 demonstrated superior head twitch response and minimal change in core body temperature, which suggests our compound potentially produces a greater hallucinogenic response with an improved safety profile'..."

New molecule • CNS Disorders • Depression